Next Article in Journal
2'-[(4-Fluorophenyl)carbonyl]-1'-phenyl-1',2',5',6',7',7a'-hexahydrospiro[indole-3,3'-pyrrolizin]-2(1H)-one
Previous Article in Journal
2-{[5-(Diphenylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(pyrazin-2-yl)acetamide
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

(R)-7-(Azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride

R&D Center, Jiangsu Yabang Pharmaceutical Group, Changzhou 213200, China
*
Author to whom correspondence should be addressed.
Molbank 2013, 2013(2), M801; https://doi.org/10.3390/M801
Submission received: 15 April 2013 / Accepted: 13 May 2013 / Published: 22 May 2013

Abstract

:
In this paper (R)-7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride 1 was isolated and identified as the N-substituted regioisomer of besifloxacin, which has been synthesized from the reaction of 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 3 with (R)-tert-butyl 3-aminoazepane-1-carboxylate 2 in acetonitrile as solvent in 37% yield. The chemical structure of compound 1 was established on the basis of 1H-NMR, 13C-NMR, mass spectrometry data and elemental analysis.

Graphical Abstract

Besifloxacin, (+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride, developed by SS Pharmaceutical (SSP) Co. Ltd. (Figure 1), was a fourth-generation fluoroquinolone antibiotic [1,2,3,4,5]. Besifloxacin hydrochloride eye drop was used to treat bacterial conjunctivitis caused by aerobic and facultative Gram-positive microorganisms and aerobic and facultative Gram-negative microorganisms.
Recently, we found a new compound 1, (R)-7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride was always present during the synthesis of besifloxacin. It was found that 1 was the N-substituted regioisomer of besifloxacin.
As a part of our research programme on besifloxacin, we report herein the synthesis of the compound 1 through 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 3 with (R)-tert-butyl 3-aminoazepane-1-carboxylate 2 in acetonitrile in the presence of catalytic amounts of triethylamine (Scheme 1). And then it was deprotected with hydrochloric acid to get the target compound 1 [6,7,8]. The total yield was 37%.
The 1H-NMR spectrum of compound 1 was different from besifloxacin. The 1H-NMR spectrum of compound 1 showed a doublet located at δ 6.20 ppm (J = 9.1 Hz )which was assigned to the one H-11 proton of -NH-. A singlet was located at δ 9.72 ppm indicated two H-14 protons of the amine hydrochloride. The 1H-NMR spectrum of besifloxacin showed a singlet located at δ 8.23 ppm which was assigned to the three H-23' protons of the amine hydrochloride.

Experimental

1H-NMR and 13C-NMR spectra were obtained using a Bruker Avance AV-500 spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany) and were recorded at 500 MHz and 125 MHz respectively. All the experiments were carried out in DMSO-d6. Chemical shifts are expressed in ppm (δ) with tetramethylsilane (TMS) as an internal standard.
The 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 3 [9] and (R)-tert-butyl 3-aminoazepane-1-carboxylate 2 [10] were obtained by R&D Center, Jiangsu Yabang Pharmaceutical Group.
To a solution of 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 3 (3.00 g, 10 mmol), in dry acetonitrile (15 mL) was added to triethylamine (2.00 g, 20 mmol) at 0 °C. After 15 min, a solution of (R)-tert-butyl 3-aminoazepane-1-carboxylate 2 (2.14 g, 10 mmol) in anhydrous acetonitrile (5 mL) was added and the mixture was refluxed for 5 h. Then the mixture was concentrated to dryness, dissolved in CH2Cl2 (30 mL), washed with brine (15 mL × 3), followed by concentrated and recrystallized from 95% ethanol to give a white solid. The white solid dissolved in 4 mol/L HCl-ethanol solution, then heated at 37 °C for 2 h. After concentrated to dryness and recrystallized by 95% ethanol to give compound 1 as pale yellowish-white powder.
Yield: 37%; m.p.: 224–225 °C pale yellowish-white powder.

Structural Characterization

1H-NMR (500 MHz, DMSO-d6): δ ppm: 14.73 (H-23, s, 1H), 9.72 (H-14, s, 2H), 8.69 (H-7, s, 1H), 7.79 (H-1, d, J = 13.1 Hz, 1H), 6.20 (H-11, d, J = 9.1 Hz, 1H), 4.37 (H-12 and H-19, m, 2H), 3.38 (H-13, m, 2H), 3.23 (H-15, m, 1H), 3.09 (H-15, m, 1H), 2.14 (H-18, m, 1H), 1.94 (H-16 and H-18, m, 2H), 1.84 (H-16 and H-17, m, 2H), 1.60 (H-17, m, 1H), 1.23 (H-20 or H-21, m, 2H), 1.03 (H-20 or H-21, m, 2H).
13C-NMR(125 MHz, DMSO-d6): δ ppm: 175.6 (C-9), 165.4 (C-22), 151.7 (C-7), 150.6 (C-2), 148.7 (C-3), 139.0 (C-5), 137.3 (C-4), 117.8 (C-10), 110.3 (C-1), 107.0 (C-8), 52.9 (C-12), 50.1 (C-13), 46.2 (C-15), 41.3 (C-19), 34.0 (C-18), 24.9 (C-16), 21.6 (C-17), 10.9 (C-20 or C-21).
FAB-MS, m/z = 394.1 (M+).
Elemental analysis: Calculated for C19H21ClFN3O3.HCl: C, 53.03%; H, 5.15%; N, 9.77%; found: C, 52.82%; H, 5.39%; N, 9.50%.

Supplementary materials

Supplementary File 1Supplementary File 2Supplementary File 3Supplementary File 4

Acknowledgements

Authors are thankful to China Pharmaceutical University for providing the spectra data. The sample of compound 1, 2, and 3 were provided by R&D Center, Jiangsu Yabang Pharmaceutical Group is also acknowledged.

References and Notes

  1. Haas, W.; Pillar, C.M.; Zurenko, G.E.; Lee, J.C.; Brunner, L.S.; Morris, T.W. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against acrobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009, 53, 3552–3560. [Google Scholar] [CrossRef] [PubMed]
  2. Tepedino, M.E.; Heller, W.H.; Usner, D.W.; Brunner, L.S.; Morris, T.W.; Haas, W.; Paterno, M.R.; Comstock, T.L. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 2009, 25, 1159–1169. [Google Scholar] [CrossRef] [PubMed]
  3. Karpecki, P.; DePaolis, M.; Hunter, J.A.; White, E.M.; Rigel, L.; Brunner, L.S.; Usner, D.W.; Paterno, M.R.; Comstock, T.L. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin. Ther. 2009, 31, 514–526. [Google Scholar] [CrossRef] [PubMed]
  4. McDonald, M.B.; Protzko, E.E.; Brunner, L.S.; Morris, T.W.; Haas, W.; Paterno, M.R.; Comstock, T.L.; Usner, D.W. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009, 116, 1615–1623. [Google Scholar] [CrossRef] [PubMed]
  5. Yoshida, J.; Kim, A.; Pratzer, K.A.; Stark, W.J. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J. Cataract Refract. Surg. 2010, 36, 1499–1502. [Google Scholar] [CrossRef] [PubMed]
  6. Harms, A.E.; Ramakrishnan, A.; Soni, A.K. Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same. U.S. Patent 8252783, 17 September 2009. [Google Scholar]
  7. Pellegata, R.; Pinza, M.; Pifferi, G. An improved synthesis of γ-, δ-, and ε-lactams. Synthesis 1978, 1978, 614–616. [Google Scholar] [CrossRef]
  8. Boyle, W.J.; Sifniades, S.; Peppen, J.F. Asymmetric transformation of α-amino-ε-caprolactam, a ysine precursor. J. Org. Chem. 1979, 44, 4841–4847. [Google Scholar] [CrossRef]
  9. Irakura, T.; Suzue, S.; Murayama, S.; Hirai, K.; Ishizaki, T. Quinolinecarboxylic Acid Derivatives and Process for Their Preparation. Eur. Pat. Appl. 0195841, 1 October 1986. [Google Scholar]
  10. Sanchez, J.P.; Domagala, J.M.; Hagen, S.E.; Heifetz, C.L.; Hutt, M.P.; Nichols, J.B.; Trehan, A.K. Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J. Med. Chem. 1988, 31, 983–991. [Google Scholar] [CrossRef] [PubMed]
Figure 1. The structure of besifloxacin.
Figure 1. The structure of besifloxacin.
Molbank 2013 m801 g001
Scheme 1. Synthesis of (R)-7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.
Scheme 1. Synthesis of (R)-7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.
Molbank 2013 m801 sch001

Share and Cite

MDPI and ACS Style

Xia, Z.; Chen, Z.; Yu, S. (R)-7-(Azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride. Molbank 2013, 2013, M801. https://doi.org/10.3390/M801

AMA Style

Xia Z, Chen Z, Yu S. (R)-7-(Azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride. Molbank. 2013; 2013(2):M801. https://doi.org/10.3390/M801

Chicago/Turabian Style

Xia, Zhengjun, Zaixin Chen, and Shuitao Yu. 2013. "(R)-7-(Azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride" Molbank 2013, no. 2: M801. https://doi.org/10.3390/M801

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop